KyDo Therapeutics has Secured a Seed Extension Financing from Existing Investors Following Promising New Preclinical Data

- **KyDo has secured a seed extension financing from existing investors, including management and founders, to further strengthen its covalent-allosteric oncology platform.**
- **New compelling preclinical data of KyDo's lead program further underscore its potential to deliver best-in-class oncology therapeutics.**

November 4th, 2026, Dortmund, Germany – KyDo Therapeutics GmbH (KyDo), a preclinical-stage biotechnology company developing novel covalent-allosteric small-molecule inhibitors for the treatment of genetically defined cancers, today announced that it has secured a seed extension financing from its existing investors, including members of the management team and the company's founders.

The financing follows a series of promising new preclinical data supporting the potential of KyDo's lead program and provides the company with additional runway to advance its development activities and generate further value-defining data.

"We are very pleased to have secured the continued support of our existing investors at this important stage of the company's development," said Matthias Stein-Gerlach, CEO of KyDo Therapeutics. "The decision of our investors, including management and our founders, to further support KyDo reflects their confidence in the scientific progress we have achieved and in the potential of our approach. The latest data have further strengthened our conviction that our covalent-allosteric approach may offer a differentiated opportunity to address important limitations of current targeted cancer therapies."

The new financing will enable KyDo to continue advancing its lead program towards DC nomination, while further characterizing the therapeutic potential and differentiation of its proprietary compounds.

KyDo's drug discovery platform is based on covalent-allosteric modulation of a clinically validated cancer target. By combining the advantages of covalent binding with allosteric target modulation, the company aims to develop highly potent and selective inhibitors with the potential to overcome resistance mechanisms and address cancer variants for which effective treatment options remain limited.

KyDo will continue to engage with investors and potential strategic partners as the company advances its lead program and builds the data package required for future investments and partnering opportunities.

###

About KyDo Therapeutics GmbH

KyDo Therapeutics GmbH (KyDo) is a preclinical-stage biotechnology company based in Dortmund, Germany, focused on the discovery and development of novel covalent-allosteric small-molecule inhibitors for the treatment of cancer. KyDo's proprietary approach aims to address a clinically validated and highly relevant oncology target.

KyDo was jointly founded by Lead Discovery Center GmbH (LDC) and scientists from the Rauh Lab at TU Dortmund University. The company successfully completed a €4.45 million seed financing round in 2025, led by i&i Biotech Fund I SCSp together with KHAN Technology Transfer Fund II GmbH & Co KG (KHAN-II) and with participation from VORNvc and TU capital. In 2026, KyDo was awarded the MATWIN prize for the best drug-based innovation project in oncology.

Further information at: https://kydo-tx.com

###

KyDo contact:
KyDo Therapeutics GmbH
Dortmund, Germany
Dr. Matthias Stein-Gerlach
E-Mail: info@kydo-tx.com

LDC/KHAN contact:
E-mail: pr@lead-discovery.de

###